This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Five Dumbest Things on Wall Street This Week: Feb. 15

5. EnteroMedics Gets Zapped

If only EnteroMedics' (ETRM) diet device could slim obese patients as well as it did the company's stock price, then the company's shareholders would be in a much weightier position.

Shares of EnteroMedics plummeted 56% to $1.26 last Friday, after it reported disappointing clinical trial results for its Maestro System, which uses electrical charges to block the primary nerve regulating digestion. Unlike pacemakers, patients power the surgically implanted device on and off with a control belt worn around the waist.

Top-line results from the 233 person phase III study known as ReCharge showed that patients implanted with an active Maestro device lost just 8.5% more "excess weight" than those implanted with a dummy device. In order for the study to be successful, Maestro needed to hit a 10% statistical superiority margin over the sham device, according to TheStreet's biotech ax Adam Feuerstein.

In other words, for all its pumped-up publicity, EnteroMedics' fat zapper turned out to be nothing more than a pulsing placebo.

Nevertheless, the less-than-impressive ReCharge results are still not stopping the company from filing for marketing clearance with the Food and Drug Administration during the second quarter.

"Based on these compelling results, and the totality of our clinical experience with the Maestro System, which now includes more than 600 patients worldwide, we believe EnteroMedics is well-positioned to deliver this novel therapy to people with obesity in the U.S.," said the company's CEO, Dr. Mark B. Knudson.

No way, Knudson. No matter how you try and spin it, those results were anything but "compelling." And even in the unlikely case that the FDA approves your device despite two failed phase III studies, why would anybody shock themselves svelte when they will soon be able to simply pop a diet pill from the likes of Arena (ARNA), Vivus (VVUS) or Orexigen (OREX)?

Like it or not, that's the real skinny on EnteroMedics.
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
DELL $0.00 0.00%
AAPL $120.05 -1.00%
CCL $52.37 -1.70%
ETRM $0.31 0.65%
TSLA $264.30 -0.70%

Markets

Chart of I:DJI
DOW 17,611.95 -77.91 -0.44%
S&P 500 2,102.21 -1.63 -0.08%
NASDAQ 5,133.1080 +4.8270 0.09%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs